Taro Shimizu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6379796/publications.pdf

Version: 2024-02-01

75 papers	2,799 citations	201575 27 h-index	182361 51 g-index
77 all docs	77 docs citations	77 times ranked	3241 citing authors

#	Article	IF	Citations
1	PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner. Journal of Controlled Release, 2007, 122, 349-355.	4.8	333
2	Anti-PEG antibodies: Properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals. Advanced Drug Delivery Reviews, 2020, 154-155, 163-175.	6.6	332
3	PEGylated liposomes: immunological responses. Science and Technology of Advanced Materials, 2019, 20, 710-724.	2.8	287
4	Anti-PEG IgM Is a Major Contributor to the Accelerated Blood Clearance of Polyethylene Glycol-Conjugated Protein. Molecular Pharmaceutics, 2015, 12, 2429-2435.	2.3	154
5	Anti-PEG IgM Response against PEGylated Liposomes in Mice and Rats. Pharmaceutics, 2011, 3, 1-11.	2.0	120
6	Improved anticancer effects of albumin-bound paclitaxel nanoparticle via augmentation of EPR effect and albumin-protein interactions using S-nitrosated human serum albumin dimer. Biomaterials, 2017, 140, 162-169.	5.7	114
7	Use of polyglycerol (PG), instead of polyethylene glycol (PEG), prevents induction of the accelerated blood clearance phenomenon against long-circulating liposomes upon repeated administration. International Journal of Pharmaceutics, 2013, 456, 235-242.	2.6	90
8	Intravenous Administration of Polyethylene Glycol-Coated (PEGylated) Proteins and PEGylated Adenovirus Elicits an Anti-PEG Immunoglobulin M Response. Biological and Pharmaceutical Bulletin, 2012, 35, 1336-1342.	0.6	81
9	Effect of siRNA in PEG-coated siRNA-lipoplex on anti-PEG IgM production. Journal of Controlled Release, 2009, 137, 234-240.	4.8	73
10	CpG motifs in pDNA-sequences increase anti-PEG IgM production induced by PEG-coated pDNA-lipoplexes. Journal of Controlled Release, 2010, 142, 160-166.	4.8	71
11	Anti-PEG IgM and complement system are required for the association of second doses of PEGylated liposomes with splenic marginal zone B cells. Immunobiology, 2015, 220, 1151-1160.	0.8	70
12	Transport of PEGylated liposomes from the splenic marginal zone to the follicle in the induction phase of the accelerated blood clearance phenomenon. Immunobiology, 2013, 218, 725-732.	0.8	68
13	A Novel Strategy to Increase the Yield of Exosomes (Extracellular Vesicles) for an Expansion of Basic Research. Biological and Pharmaceutical Bulletin, 2018, 41, 733-742.	0.6	54
14	A hydroxyl PEG version of PEGylated liposomes and its impact on anti-PEG IgM induction and on the accelerated clearance of PEGylated liposomes. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 127, 142-149.	2.0	53
15	Relationship between the Concentration of Anti-polyethylene Glycol (PEG) Immunoglobulin M (IgM) and the Intensity of the Accelerated Blood Clearance (ABC) Phenomenon against PEGylated Liposomes in Mice. Biological and Pharmaceutical Bulletin, 2015, 38, 417-424.	0.6	46
16	Cancer cell-type tropism is one of crucial determinants for the efficient systemic delivery of cancer cell-derived exosomes to tumor tissues. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 145, 27-34.	2.0	44
17	Ganglioside inserted into PEGylated liposome attenuates anti-PEG immunity. Journal of Controlled Release, 2017, 250, 20-26.	4.8	43
18	Generation, characterization and in vivo biological activity of two distinct monoclonal anti-PEG IgMs. Toxicology and Applied Pharmacology, 2014, 277, 30-38.	1.3	37

#	Article	IF	Citations
19	Evidence for Delivery of Abraxane via a Denatured-Albumin Transport System. ACS Applied Materials & Interfaces, 2021, 13, 19736-19744.	4.0	34
20	Quantitative determination of polysulfide in albumins, plasma proteins and biological fluid samples using a novel combined assays approach. Analytica Chimica Acta, 2017, 969, 18-25.	2.6	33
21	Hepatosplenic phagocytic cells indirectly contribute to anti-PEG IgM production in the accelerated blood clearance (ABC) phenomenon against PEGylated liposomes: Appearance of an unexplained mechanism in the ABC phenomenon. Journal of Controlled Release, 2020, 323, 102-109.	4.8	32
22	Anti-PEG IgM production and accelerated blood clearance phenomenon after the administration of PEGylated exosomes in mice. Journal of Controlled Release, 2021, 334, 327-334.	4.8	32
23	Liposome co-incubation with cancer cells secreted exosomes (extracellular vesicles) with different proteins expressions and different uptake pathways. Scientific Reports, 2018, 8, 14493.	1.6	31
24	Long-term storage of PEGylated liposomal oxaliplatin with improved stability and long circulation times in vivo. International Journal of Pharmaceutics, 2019, 564, 237-243.	2.6	30
25	Advanced therapeutic approach for the treatment of malignant pleural mesothelioma via the intrapleural administration of liposomal pemetrexed. Journal of Controlled Release, 2015, 220, 29-36.	4.8	29
26	A novel S-sulfhydrated human serum albumin preparation suppresses melanin synthesis. Redox Biology, 2018, 14, 354-360.	3.9	29
27	Aseptic meningitis after vaccination of the BNT162b2 mRNA COVID-19 vaccine. Neurological Sciences, 2021, 42, 4433-4435.	0.9	29
28	Involvement of complement activation in the pulmonary vasoactivity of polystyrene nanoparticles in pigs: unique surface properties underlying alternative pathway activation and instant opsonization. International Journal of Nanomedicine, 2018, Volume 13, 6345-6357.	3.3	28
29	A Novel Platform for Cancer Vaccines: Antigen-Selective Delivery to Splenic Marginal Zone B Cells via Repeated Injections of PEGylated Liposomes. Journal of Immunology, 2018, 201, 2969-2976.	0.4	25
30	<i>Ex-Vivo</i>/<i>in-Vitro</i> Anti-polyethylene Glycol (PEG) Immunoglobulin M Production from Murine Splenic B Cells Stimulated by PEGylated Liposome. Biological and Pharmaceutical Bulletin, 2013, 36, 1842-1848.	0.6	24
31	B cell-intrinsic toll-like receptor 7 is responsible for the enhanced anti-PEG IgM production following injection of siRNA-containing PEGylated lipoplex in mice. Journal of Controlled Release, 2014, 184, 1-8.	4.8	23
32	Modulation of antitumor immunity contributes to the enhanced therapeutic efficacy of liposomal oxaliplatin in mouse model. Cancer Science, 2017, 108, 1864-1869.	1.7	21
33	Cell-penetrating mechanism of intracellular targeting albumin: Contribution of macropinocytosis induction and endosomal escape. Journal of Controlled Release, 2019, 304, 156-163.	4.8	19
34	Pegfilgrastim (PEG-G-CSF) induces anti-PEG IgM in a dose dependent manner and causes the accelerated blood clearance (ABC) phenomenon upon repeated administration in mice. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 152, 56-62.	2.0	19
35	Complement activation induced by PEG enhances humoral immune responses against antigens encapsulated in PEG-modified liposomes. Journal of Controlled Release, 2021, 329, 1046-1053.	4.8	17
36	Lysophosphatidic acid in medicinal herbs enhances prostaglandin E2 and protects against indomethacin-induced gastric cell damage in vivo and in vitro. Prostaglandins and Other Lipid Mediators, 2018, 135, 36-44.	1.0	16

#	Article	IF	Citations
37	A Cell Assay for Detecting Anti-PEG Immune Response against PEG-Modified Therapeutics. Pharmaceutical Research, 2018, 35, 223.	1.7	16
38	Distribution of Polysulfide in Human Biological Fluids and Their Association with Amylase and Sperm Activities. Molecules, 2019, 24, 1689.	1.7	15
39	Comprehensive analysis of PEGylated liposomeâ€associated proteins relating to the accelerated blood clearance phenomenon by combination with shotgun analysis and conventional methods. Biotechnology and Applied Biochemistry, 2015, 62, 547-555.	1.4	13
40	Intratumoral Visualization of Oxaliplatin within a Liposomal Formulation Using X-ray Fluorescence Spectrometry. Molecular Pharmaceutics, 2018, 15, 403-409.	2.3	13
41	Doxorubicin Expands <i>in Vivo</i> Secretion of Circulating Exosome in Mice. Biological and Pharmaceutical Bulletin, 2018, 41, 1078-1083.	0.6	13
42	Impact of Pre-Existing or Induced Anti-PEG IgM on the Pharmacokinetics of Peginterferon Alfa-2a (Pegasys) in Mice. Molecular Pharmaceutics, 2020, 17, 2964-2970.	2.3	13
43	Therapeutic efficacy of a paclitaxel-loaded nanofibrillated bacterial cellulose (PTX/NFBC) formulation in a peritoneally disseminated gastric cancer xenograft model. International Journal of Biological Macromolecules, 2021, 174, 494-501.	3.6	13
44	Improvement of intratumor microdistribution of PEGylated liposome via tumor priming by metronomic S-1 dosing. International Journal of Nanomedicine, 2016, Volume 11, 5573-5582.	3.3	12
45	Reactivity of IgM antibodies elicited by PEGylated liposomes or PEGylated lipoplexes against auto and foreign antigens. Journal of Controlled Release, 2018, 270, 114-119.	4.8	12
46	Hepatic Tumor Metastases Cause Enhanced PEGylated Liposome Uptake by Kupffer Cells. Biological and Pharmaceutical Bulletin, 2016, 39, 215-220.	0.6	10
47	Increasing Tumor Extracellular pH by an Oral Alkalinizing Agent Improves Antitumor Responses of Anti-PD-1 Antibody: Implication of Relationships between Serum Bicarbonate Concentrations, Urinary pH, and Therapeutic Outcomes. Biological and Pharmaceutical Bulletin, 2021, 44, 844-852.	0.6	10
48	Pegfilgrastim (PEG-G-CSF) Induces Anti-polyethylene Glycol (PEG) IgM <i>via</i> a T Cell-Dependent Mechanism. Biological and Pharmaceutical Bulletin, 2020, 43, 1393-1397.	0.6	10
49	PEGylation and anti-PEG antibodies. , 2018, , 51-68.		9
50	Reduction-Responsive and Multidrug Deliverable Albumin Nanoparticles: An Antitumor Drug to Abraxane against Human Pancreatic Tumor-Bearing Mice. ACS Applied Bio Materials, 2021, 4, 4302-4309.	2.3	9
51	Nucleic acids delivered by PEGylated cationic liposomes in systemic lupus erythematosus-prone mice: A possible exacerbation of lupus nephritis in the presence of pre-existing anti-nucleic acid antibodies. International Journal of Pharmaceutics, 2021, 601, 120529.	2.6	8
52	A novel intraperitoneal therapy for gastric cancer with DFPâ€10825, a unique RNAi therapeutic targeting thymidylate synthase, in a peritoneally disseminated xenograft model. Cancer Medicine, 2019, 8, 7313-7321.	1.3	7
53	An immediate hypersensitivity reaction induced by PEGylated recombinant factor VIII. Haemophilia, 2020, 26, e236-e239.	1.0	7
54	A simplified method for manufacturing RNAi therapeutics for local administration. International Journal of Pharmaceutics, 2019, 564, 256-262.	2.6	5

#	Article	IF	Citations
55	Adjuvant Antitumor Immunity Contributes to the Overall Antitumor Effect of Pegylated Liposomal Doxorubicin (DoxilÂ®) in C26 Tumor-Bearing Immunocompetent Mice. Pharmaceutics, 2020, 12, 990.	2.0	5
56	Blood retention and antigenicity of polycarboxybetaine-modified liposomes. International Journal of Pharmaceutics, 2020, 586, 119521.	2.6	5
57	A Unique Gene-Silencing Approach, Using an Intelligent RNA Expression Device (iRed), Results in Minimal Immune Stimulation When Given by Local Intrapleural Injection in Malignant Pleural Mesothelioma. Molecules, 2020, 25, 1725.	1.7	5
58	Doxorubicin Embedded into Nanofibrillated Bacterial Cellulose (NFBC) Produces a Promising Therapeutic Outcome for Peritoneally Metastatic Gastric Cancer in Mice Models via Intraperitoneal Direct Injection. Nanomaterials, 2021, 11, 1697.	1.9	5
59	The Therapeutic Effect of Human Serum Albumin Dimer-Doxorubicin Complex against Human Pancreatic Tumors. Pharmaceutics, 2021, 13, 1209.	2.0	5
60	A mouse model for studying the effect of blood anti-PEG IgMs levels on the in vivo fate of PEGylated liposomes. International Journal of Pharmaceutics, 2022, 615, 121539.	2.6	5
61	Lymphoid follicle antigen (Ag) delivery and enhanced rodent humoral immune responses mediated by Ag-containing PEGylated liposomes. Vaccine, 2021, 39, 1131-1139.	1.7	4
62	Incorporating Gangliosides into PEGylated Cationic Liposomes that Complexed DNA Attenuates Anti-PEG Antibody Production but Not Anti-DNA Antibody Production in Mice. Molecular Pharmaceutics, 2021, 18, 2406-2415.	2.3	4
63	I.p.-injected cationic liposomes are retained and accumulate in peritoneally disseminated tumors. Journal of Controlled Release, 2022, 341, 524-532.	4.8	4
64	Hydrodynamic Tail Vein Injection as a Simple Tool for Yielding Extended Transgene Expression in Solid Tumors. Biological and Pharmaceutical Bulletin, 2016, 39, 1555-1558.	0.6	3
65	Liposomalization of Oxaliplatin Exacerbates the Non-Liposomal Formulation-Induced Decrease of Sweet Taste Sensitivity in Rats. Journal of Pharmaceutical Sciences, 2021, 110, 3937-3945.	1.6	2
66	Pharmaceutics of Nanoparticles. Methods in Pharmacology and Toxicology, 2016, , 219-238.	0.1	2
67	Development of an Antigen Delivery System for a B Cell-Targeted Vaccine as an Alternative to Dendritic Cell-Targeted Vaccines. Chemical and Pharmaceutical Bulletin, 2022, 70, 341-350.	0.6	2
68	The Challenge to Deliver Oxaliplatin (l-OHP) to Solid Tumors: Development of Liposomal l-OHP Formulations. Chemical and Pharmaceutical Bulletin, 2022, 70, 351-358.	0.6	2
69	Characteristics, evaluation and suppression of anti-poly(ethylene glycol) antibody. Drug Delivery System, 2016, 31, 300-307.	0.0	1
70	Animal species difference in the ABC phenomenon. Drug Delivery System, 2017, 32, 396-401.	0.0	1
71	Using Bio-Layer Interferometry to Evaluate Anti-PEG Antibody-Mediated Complement Activation. Biological and Pharmaceutical Bulletin, 2022, 45, 129-135.	0.6	1
72	Development of a Nanocarrier-Based Splenic B Cell-Targeting System for Loading Antigens <i>in Vitro</i>. Biological and Pharmaceutical Bulletin, 2022, 45, 926-933.	0.6	1

#	Article	IF	Citations
73	Merit and demerit of complement activation by nanoparticles. Drug Delivery System, 2017, 32, 199-207.	0.0	0
74	Liposome Research Days 2019. Drug Delivery System, 2019, 34, 402-403.	0.0	0
75	Importance of Understanding Immune Reaction and Pharmacokinetic on the Development of Liposomal DDS Formulations. Oleoscience, 2020, 20, 71-76.	0.0	0